Home › Marginal Zone Lymphoma › California
Marginal Zone Lymphoma clinical trials in California
18 studies for Marginal Zone Lymphoma are looking for participants at sites in California.
Cities in California
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07583810A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- City of Hope at Irvine Lennar, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
- City of Hope National Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05296070A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- David Geffen School of Medicine at UCLA, Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06149286AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- University of California Davis Comprehensive Cancer Center, Sacramento
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06905509Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT04545762Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06859008A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.